Scale-Up and Manufacturing of Regenerative Medicine

Scale-Up and Manufacturing of Regenerative Medicine

When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this Q&A interview, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.


Please note: That all fields marked with an asterisk (*) are required.